Filtered By:
Specialty: General Medicine
Drug: Clopidogrel

This page shows you your search results in order of relevance. This is page number 9.

Order by Relevance | Date

Total 188 results found since Jan 2013.

Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Conclusion: Among real-world Chinese patients with ACS treated by PCI, ticagrelor only showed superior efficacy in patients with low bleeding risk but lost its advantage in patients with moderate-to-high bleeding potential. PMID: 30127210 [PubMed - in process]
Source: Chinese Medical Journal - August 23, 2018 Category: General Medicine Authors: Wang HY, Li Y, Xu XM, Li J, Han YL Tags: Chin Med J (Engl) Source Type: research

Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial
Publication date: Available online 25 August 2018Source: The LancetAuthor(s): Marco Valgimigli, Enrico Frigoli, Sergio Leonardi, Pascal Vranckx, Martina Rothenbühler, Matteo Tebaldi, Ferdinando Varbella, Paolo Calabrò, Stefano Garducci, Paolo Rubartelli, Carlo Briguori, Giuseppe Andó, Maurizio Ferrario, Ugo Limbruno, Roberto Garbo, Paolo Sganzerla, Filippo Russo, Marco Nazzaro, Alessandro Lupi, Bernardo CorteseSummaryBackgroundThe Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX) programme was designed to assess the comparative safety and effectiveness of ra...
Source: The Lancet - August 25, 2018 Category: General Medicine Source Type: research

Aortic stenosis in the elderly: The TAVI revolution.
Abstract TAVI is currently recommended for severe symptomatic aortic stenosis in patients at prohibitive, high or intermediate surgical risk as estimated by surgical risk scores (STS score and EuroSCORE II). Comorbidity, technical feasibility of TAVI and concurrent pathology with need for complementary surgical correction are conditions to be considered to choose between open surgery and TAVI. The decision is often made by the "Heart Team". The transfemoral access must be favored. Conduction disturbance, stroke, bioprosthesis thrombosis and durability are the main setbacks of TAVI. Double antiplatelet therapy with...
Source: Presse Medicale - December 10, 2018 Category: General Medicine Authors: Overtchouk P, Collet JP Tags: Presse Med Source Type: research

Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis
Source: BMJ - December 18, 2018 Category: General Medicine Source Type: research

Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial
Source: BMJ - June 7, 2019 Category: General Medicine Source Type: research

Association of lipoprotein(a) and major adverse cardiovascular events in patients with percutaneous coronary intervention.
Conclusions: Baseline serum Lp(a) can be used to predict MACEs in patients after PCI treatment, which was independent of LDL-C. PMID: 31749864 [PubMed]
Source: Archives of Medical Science - November 23, 2019 Category: General Medicine Tags: Arch Med Sci Source Type: research

Net Adverse Clinical Events With Antiplatelet Therapy in Acute Coronary Syndromes
Clopidogrel, prasugrel, and ticagrelor are oral platelet P2Y12 receptor inhibitors that decrease the risk of platelet-mediated coronary artery thrombosis. Clinical guidelines have recommended ticagrelor or prasugrel over clopidogrel in combination with aspirin as dual antiplatelet therapy (DAPT) for 1 year after acute coronary syndrome (ACS), whether or not percutaneous coronary intervention (PCI) is performed. The ticagrelor recommendation was based on the Study of Platelet Inhibition and Patient Outcomes (PLATO) trial, which enrolled 18  624 patients with ACS and randomized them to receive DAPT with either clopidogrel ...
Source: JAMA - October 27, 2020 Category: General Medicine Source Type: research

Clinical Outcomes of Ticagrelor in Korean Patients with Acute Myocardial Infarction without High Bleeding Risk
CONCLUSIONS: The bleeding risk of ticagrelor was attenuated in Korean patients with AMI without HBR. Appropriate patient selection could reduce in-hospital bleeding complications associated with ticagrelor in Korean patients with AMI who underwent successful PCI.PMID:34725976 | DOI:10.3346/jkms.2021.36.e268
Source: J Korean Med Sci - November 2, 2021 Category: General Medicine Authors: Keun-Ho Park Myung Ho Jeong Hyun Kuk Kim Young-Jae Ki Sung Soo Kim Dong-Hyun Choi Young-Youp Koh Youngkeun Ahn Hyo-Soo Kim Hyeon-Cheol Gwon Seung-Woon Rha Jin-Yong Hwang KAMIR-NIH registry investigators Source Type: research

Expert Opinion on P2Y12 Inhibitors Use in Management of Acute Coronary Syndromes: Focus on Ticagrelor
In conclusion, ticagrelor (180 mg, 90 mg, and 60 mg doses), a potent antiplatelet is expected to reshape the antiplatelet use in the management of ACS.PMID:34781659
Source: Journal of the Association of Physicians of India - November 16, 2021 Category: General Medicine Authors: Immaneni Sathyamurthy M S Hiremath Jitendra Pal Sawhney Subhash Chandra Hrudanand Mishra C K Ponde Shuvanan Ray Suhas Hardas Sunil Sathe P C Rath Bagirath R Girish B Navasundi Vilas Magarkar C N Makhale Suvro Banerjee P R Vaidyanathan Amal Kanti Sen Pande Source Type: research